WO2013022312A3 - C y p 4 a 저해제를 유효성분으로 함유하는 당뇨병 또는 지방간의 예방 또는 치료용 약학적 조성물 - Google Patents

C y p 4 a 저해제를 유효성분으로 함유하는 당뇨병 또는 지방간의 예방 또는 치료용 약학적 조성물 Download PDF

Info

Publication number
WO2013022312A3
WO2013022312A3 PCT/KR2012/006395 KR2012006395W WO2013022312A3 WO 2013022312 A3 WO2013022312 A3 WO 2013022312A3 KR 2012006395 W KR2012006395 W KR 2012006395W WO 2013022312 A3 WO2013022312 A3 WO 2013022312A3
Authority
WO
WIPO (PCT)
Prior art keywords
preventing
treating diabetes
fatty liver
pharmaceutical composition
active ingredient
Prior art date
Application number
PCT/KR2012/006395
Other languages
English (en)
French (fr)
Other versions
WO2013022312A2 (ko
Inventor
김건화
김수현
최종순
김승일
박창균
Original Assignee
한국기초과학지원연구원
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 한국기초과학지원연구원 filed Critical 한국기초과학지원연구원
Priority to JP2014525926A priority Critical patent/JP5901770B2/ja
Publication of WO2013022312A2 publication Critical patent/WO2013022312A2/ko
Publication of WO2013022312A3 publication Critical patent/WO2013022312A3/ko
Priority to US14/178,090 priority patent/US9295667B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/065—Diphenyl-substituted acyclic alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

본 발명은 당뇨병 또는 지방간의 예방 또는 치료용 약학적 조성물에 관한 것으로서, 보다 상세하게는 CYP4A(cytochrome P450A) 저해제를 유효성분으로 함유하는 당뇨병 또는 지방간의 예방 또는 치료용 약학적 조성물에 관한 것이다. 본 발명에 따르면 CYP4A 저해제는 소포체 스트레스를 억제하고， 혈중 인슐린 농도를 감소시키며，간 세포의 세포사멸을 억제함으로써 당뇨병 또는 지방간의 예방 또는 치료에 효과를 나타낸다.
PCT/KR2012/006395 2011-08-11 2012-08-10 C y p 4 a 저해제를 유효성분으로 함유하는 당뇨병 또는 지방간의 예방 또는 치료용 약학적 조성물 WO2013022312A2 (ko)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2014525926A JP5901770B2 (ja) 2011-08-11 2012-08-10 Ｃｙｐ４ａ阻害剤を有効成分として含有する糖尿病又は脂肪肝の予防又は治療用薬学的組成物。
US14/178,090 US9295667B2 (en) 2011-08-11 2014-02-11 Pharmaceutical composition for preventing or treating diabetes or fatty liver containing a CYP4A inhibitor as an active ingredient

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2011-0080208 2011-08-11
KR1020110080208A KR101235811B1 (ko) 2011-08-11 2011-08-11 Ｃｙｐ４ａ 저해제를 유효성분으로 함유하는 당뇨병의 치료 또는 예방용 약학적 조성물

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/178,090 Continuation US9295667B2 (en) 2011-08-11 2014-02-11 Pharmaceutical composition for preventing or treating diabetes or fatty liver containing a CYP4A inhibitor as an active ingredient

Publications (2)

Publication Number Publication Date
WO2013022312A2 WO2013022312A2 (ko) 2013-02-14
WO2013022312A3 true WO2013022312A3 (ko) 2013-06-13

Family

ID=47669111

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/006395 WO2013022312A2 (ko) 2011-08-11 2012-08-10 C y p 4 a 저해제를 유효성분으로 함유하는 당뇨병 또는 지방간의 예방 또는 치료용 약학적 조성물

Country Status (4)

Country Link
US (1) US9295667B2 (ko)
JP (1) JP5901770B2 (ko)
KR (1) KR101235811B1 (ko)
WO (1) WO2013022312A2 (ko)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101886118B1 (ko) * 2017-05-22 2018-09-06 한국기초과학지원연구원 Cyp4a 저해 화합물을 유효성분으로 포함하는 당뇨병 및 지방간의 예방 또는 치료용 조성물
KR102068299B1 (ko) 2018-12-21 2020-01-20 한국기초과학지원연구원 Cyp4a 저해 화합물을 유효성분으로 포함하는 대사질환의 예방 또는 치료용 조성물
WO2022235091A1 (ko) 2021-05-07 2022-11-10 엠비디 주식회사 신규한 헤테로사이클 화합물 및 이의 용도
KR20230159779A (ko) 2022-05-13 2023-11-22 싸이파마 주식회사 Cyp4a 저해 화합물을 유효성분으로 포함하는, 당뇨병과 지방간염을 포함한 대사 질환의 예방 또는 치료용 조성물

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008511566A (ja) * 2004-08-28 2008-04-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ショウガ画分の調製方法およびヒトｃｙｐ酵素を阻害するためのその使用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1330240A2 (en) * 2000-11-03 2003-07-30 MCW Research Foundation Use of 20-hete synthesizing enzyme inhibitors as therapy for cerebral vascular diseases
CN1909896A (zh) * 2003-11-14 2007-02-07 Mcw研究基金会股份有限公司 调节血管生成和癌细胞增殖的方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008511566A (ja) * 2004-08-28 2008-04-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ショウガ画分の調製方法およびヒトｃｙｐ酵素を阻害するためのその使用

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ABBAVEKKE EBRUQYEZ ET AL.: "Altered Expression of Hepatic SYP2E1 and CYP4A in Obese, Diabetic ob/ob Mice, and fa/fa Zucker Rats.", BIOCHEMICAL AND PIOPHYSICAL RESEARCH COMMUNICATIONS., vol. 255, no. 2, 16 February 1999 (1999-02-16), pages 300 - 306 *
ASSAAD A. EID ET AL.: "Mechanisms ofPodocyte Injury in Diabetes.", DIABETES, vol. 58, no. 5, May 2009 (2009-05-01), pages 1201 - 1211 *
DEANNA L. KROETZ ET AL.: "Peroxisome proliferator-activated receptor alpha controls the hepatic CYP4A induction adaptive response to starvation and diabetes.", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 273, no. 47, 20 November 1998 (1998-11-20), pages 31581 - 31589 *
TAKAYUKI SEKI ET AL.: "Cytochrome P450 4A Isoform Inhibitory Profile of N-hydroxy-N' -(4-butyl-2-methylphenyl)-formamidine(HET0016), a Selective Inhibitor of 20-HETE Synthesis.", BIOLOGICAL AND PHARMACEUTICAL BULLETIN., vol. 28, no. 9, September 2005 (2005-09-01), pages 1651 - 1654 *
ZHONGLI WANG ET AL.: "Inhibition of 20-HETE attenuates diabetes-induced decreases in retinal hemodynamics.", EXPERIMENTAL EYE RESEARCH., vol. 93, no. 1, July 2011 (2011-07-01), pages 108 - 113, XP028380560 *

Also Published As

Publication number Publication date
WO2013022312A2 (ko) 2013-02-14
KR101235811B1 (ko) 2013-02-21
KR20130017643A (ko) 2013-02-20
JP5901770B2 (ja) 2016-04-13
US20140275198A1 (en) 2014-09-18
JP2014521740A (ja) 2014-08-28
US9295667B2 (en) 2016-03-29

Similar Documents

Publication Publication Date Title
PH12016500216B1 (en) Stable pharmaceutical composition and methods of using same
WO2011107749A3 (en) Pulsatile drug release
EP2638903A4 (en) GLYCEMIA ELEVATION SUPPRESSOR
EP2727605A4 (en) ANALOGUE OF POLYETHYLENE GLYCOL EXENDIN-4 OR A DERIVATIVE THEREOF, ITS PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DIABETES, CONTAINING THE SAME AS ACTIVE INGREDIENT
EP2349279A4 (en) ALDEHYDE DEHYDROGENASE MODULATORS AND METHOD OF USE THEREOF
MX2011011178A (es) Compuesto de diaciletilendiamina.
MY176018A (en) Composition useful for the treatment of lipid metabolism disorders
CL2012003523A1 (es) Método para la preparación de una composición farmacéutica que contiene un portador de oxígeno termoestable; composicion farmaceutica que contiene un portador de oxigeno altamente purificado y termoestable.
MY168212A (en) A new therapeutical composition containing apomorphine as active ingredient
WO2012162439A3 (en) Compositions comprising fusidic acid and packages therefor
MY160372A (en) Composition for improving brain function and method for improving brain function
WO2011159129A3 (ko) 신규한 로다닌 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 ａｉｄｓ 예방 또는 치료용 약학 조성물
PH12014502802B1 (en) Novel compound having ability to inhibit 11b-hsd1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient
BR112012007798A2 (pt) microcápsulas estáveis e composição para aplicação tópica e método para a preparação de microcápsulas
WO2013022312A3 (ko) C y p 4 a 저해제를 유효성분으로 함유하는 당뇨병 또는 지방간의 예방 또는 치료용 약학적 조성물
AU2013330679A8 (en) Combination drug comprising gemigliptin and metformin, and method for the preparation thereof
WO2012134169A3 (ko) 조각인 추출물을 포함하는 폐암 치료용 조성물 및 건강 기능성 식품
WO2013025073A3 (ko) 유홍초 추출물을 함유하는 당뇨합병증 예방 또는 치료용 조성물
BR112013002832A2 (pt) composição compreendendo retinol, um precursor ou um produto de reação do mesmo e um extrato vegetal de pelo menos uma planta de camomila para o tratamento de câncer
WO2012134172A3 (ko) 오미자 에틸아세테이트 분획물 또는 이로부터 분리한 우웨이지수 ｃ를 유효성분으로 포함하는 비만 예방 또는 치료용 조성물
AU2012345659A8 (en) Acamprosate formulations, methods of using the same, and combinations comprising the same
EA201390844A1 (ru) Комплексный состав, содержащий гидрохлорид лерканидипина и валсартан, и способ его получения
EP2594268A4 (en) ANGIOGENIC INHIBITORY COMPOSITION WITH MACROLACTIN A AND A DERIVATIVELY AS ACTIVE SUBSTANCES
WO2014065640A3 (ko) 외톨개모자반 추출물 또는 이의 분획물을 유효성분으로 함유하는 염증성 질환 치료 또는 예방용 조성물
WO2012134252A3 (ko) 마자인 추출물을 포함하는 신장암 치료용 조성물 및 건강 기능성 식품

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12822002

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2014525926

Country of ref document: JP

Kind code of ref document: A

122 Ep: pct application non-entry in european phase

Ref document number: 12822002

Country of ref document: EP

Kind code of ref document: A2